EGFR and non-small cell lung carcinoma: Importantly, we verified that the OS and PFS after ICIs treatment were shorter in the YAP1_High group than in the YAP1_Low group in EGFR-mutant NSCLC patients from Ren's research [26] (NCT03513666), but not in EGFR-WT NSCLC patients from GSE13522.